IGC Pharma Inc. has announced the initiation of a clinical trial site at Santa Cruz Behavioral in Puerto Rico as part of its CALMA Phase 2 clinical trial. The study is focused on evaluating IGC-AD1, a cannabinoid-based therapy, for managing agitation in Alzheimer's disease patients. This initiative addresses the higher prevalence of Alzheimer's among Puerto Ricans over age 65, which stands at approximately 12.5%. The trial aims to explore the safety and efficacy of IGC-AD1, which functions as a partial CB1 receptor agonist with anti-neuroinflammatory properties. The inclusion of diverse populations in the trial is expected to enhance the scientific validity and commercial viability of the therapy. Interested patients and caregivers are encouraged to contact Santa Cruz Behavioral in Bayamon for participation details.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.